Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells.  
  
Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor.  PRTH-101 is poised to enter Phase 1 clinical trials.  
 
PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion.  

Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.  

Biotechnology

Health Care

Life Sciences

Pharmaceutical

Incendia Therapeutics

Wendye Robbins

Vito Quaranta

Peter Cincotta

Irena Webster

Joseph Paul Eder

Thomas Schürpf

Susan G. Macdonald

Jeff Janotka

Christopher O’donnell

Mace Rothenberg

The Leadership Team at Incendia Therapeutics is responsible for steering the company's strategic direction, overseeing the development and clinical testing of innovative anti-cancer therapies like PRTH-101, and ensuring the integration of precision oncology approaches. This team, composed of experienced industry leaders and scientific experts, drives critical decision-making processes, manages cross-functional projects, and fosters partnerships to advance the company’s mission of transforming cancer treatment through novel approaches to reprogramming the tumor microenvironment.

Leadership Team

Scientific and Research Team

Research and Development

Leadership Team

About

Team members

Other teams at Incendia Therapeutics

Scientific and Research Team

Research and Development